Australia
Orthocell at forefront of growing market opportunity in regenerative musculoskeletal treatment
Orthocell Ltd (ASX:OCC) is confident that its unique regenerative medicine product portfolio can address growing market opportunities in the treatment of complex musculoskeletal disorders.
The company is pursuing a total addressable market for CelGro® and Ortho-ATI® of US$10 billion and US$7.7 billion respectively – representing a combined US$17.7 billion per annum.
This market is driven by the rising rate of musculoskeletal disorders and demand for efficient and cost-effective treatments.
CelGro® nerve repair[hhmc]
The companys CellGro collagen medical device is designed to augment surgical repair of soft tissue and represents a breakthrough is soft tissue reconstruction.
It has multiple applications in nerve, tendon and bone repair which have been demonstrated as having superior clinical performance when compared to current market leading product.
CelGro nerve repair market opportunity.
Addressable market opportunities[hhmc]
CelGro has significant global commercial potential in..
-
Australia4 years ago
Button and Diane Powellpark the school bus after three decades
-
Australia4 years ago
Button and Diane Powellpark the school bus after three decades
-
Europe2 years ago
Covid: Flights shut down as EU discusses UK virus threat
-
Europe2 years ago
Post-Brexit trade: Is red tape chaos just ‘teething trouble’ as the UK government argues?
-
Tech3 years ago
Search engine startup asks users to be the customer, not the product
-
Tech1 year ago
Sign up to The Independent’s free cryptocurrency expert panel event
-
Health2 years ago
Spain ‘to register’ those who refuse to have Covid-19 vaccine
-
Arts5 years ago
How a chain-link mosque at the Vancouver Biennale became a community hub